Short answer
Alnylam Pharmaceuticals (ALNY) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). July 30, 2026 earnings disclosure covers fiscal-year 2026 results.
Alnylam Pharmaceuticals 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- July 30, 2026 earnings disclosure covers fiscal-year 2026 results
- Press release in Exhibit 99.1 contains the substantive financial results and management commentary
- CFO Jeffrey V. Poulton signed the filing, indicating formal company authorization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Alnylam Pharmaceuticals 8-K filings
Get the next ALNY 8-K as it lands
Follow ALNY for push alerts, or ask the research agent what this filing means.